Medicare Part B: Commentary By CMS Officials
Executive Summary
CMS officials Jonathan Blum, Louis Jacques and Tamara Jensen addressed a number of Medicare Part B-related topics of interest to the biopharmaceutical industry at the FDA/CMS Summit, including reimbursement for high-priced oncology drugs, coverage with evidence development and national coverage determinations.
You may also be interested in...
Genetic Testing, But No Drugs, On Revised List Of Potential Medicare NCD Topics
CMS includes genetic testing on its updated list of potential topics for Medicare national coverage determinations, released Nov. 27. But no biopharmaceuticals are on the list this time around.
Personalized Medicine And Palmetto’s MolDx: Raising The Bar On Evidence
In a recent presentation on evidence-based reimbursement and personalized medicine, a Novartis executive highlights Medicare Part B contractor Palmetto GBA’s molecular diagnostic reimbursement initiative as one to watch.
Lilly Submits New Amyvid Data For Medicare National Coverage Analysis
Physicians in study changed their diagnosis of whether a patient had Alzheimer’s in half of cases after receiving data from PET scans using Lilly’s beta amyloid detecting tracer Amyvid. Study findings were not available when Lilly first asked CMS to conduct the coverage analysis.